Literature DB >> 27386430

Selection Criteria and Current Issues in Liver Transplantation for Hepatocellular Carcinoma.

Toshimi Kaido1.   

Abstract

Liver transplantation (LT) is an ideal treatment for hepatocellular carcinoma (HCC) because it not only resects HCCs but it also replaces the underlying damaged liver with normal tissue. However, the selection criteria are still a matter of debate. After the introduction of the Milan criteria, some expanded criteria focusing on tumor size and number have been proposed. In addition, new expanded criteria considering tumor biology have been proposed using tumor markers and (18)F-fluorodeoxyglucose positron emission tomography. This review summarizes the selection criteria in LT for HCC and introduces current issues focusing on the treatment for hepatitis C virus infection and the significance of sarcopenia in this field.

Entities:  

Keywords:  Direct-acting antiviral agents; Expanded criteria; Hepatocellular carcinoma; Liver transplantation; Sarcopenia

Year:  2016        PMID： 27386430      PMCID： PMC4906426          DOI： 10.1159/000367749

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


  32 in total

1.  Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma.

Authors:  Hisamitsu Miyaaki; Osamu Nakashima; Mina Kurogi; Katsumi Eguchi; Masamichi Kojiro
Journal:  J Gastroenterol       Date:  2007-12-25       Impact factor: 7.527

Review 2.  Liver transplantation for hepatocellular carcinoma.

Authors:  See Ching Chan
Journal:  Liver Cancer       Date:  2013-08       Impact factor: 11.740

3.  Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.

Authors:  Norah A Terrault; Mitchell L Shiffman; Anna S F Lok; Sammy Saab; Lan Tong; Robert S Brown; Gregory T Everson; K Rajender Reddy; Jeffrey H Fair; Laura M Kulik; Timothy L Pruett; Leonard B Seeff
Journal:  Liver Transpl       Date:  2007-01       Impact factor: 5.799

4.  The Use of Donation After Cardiac Death Allografts Does Not Increase Recurrence of Hepatocellular Carcinoma.

Authors:  K P Croome; D D Lee; J M Burns; K Musto; D Paz; J H Nguyen; D K Perry; D M Harnois; C B Taner
Journal:  Am J Transplant       Date:  2015-05-12       Impact factor: 8.086

5.  Usefulness of the Kyoto criteria as expanded selection criteria for liver transplantation for hepatocellular carcinoma.

Authors:  Toshimi Kaido; Kohei Ogawa; Akira Mori; Yasuhiro Fujimoto; Takashi Ito; Koji Tomiyama; Yasutsugu Takada; Shinji Uemoto
Journal:  Surgery       Date:  2013-09-24       Impact factor: 3.982

6.  Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C.

Authors:  Yoshihide Ueda; Toshimi Kaido; Etsuro Hatano; Shigeru Ohtsuru; Shinji Uemoto
Journal:  Hepatol Res       Date:  2015-04-27       Impact factor: 4.288

7.  Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People.

Authors:  Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni
Journal:  Age Ageing       Date:  2010-04-13       Impact factor: 10.668

8.  Living donor liver transplantation for patients with HCC exceeding the Milan criteria: a proposal of expanded criteria.

Authors:  Yasutsugu Takada; Takashi Ito; Mikiko Ueda; Seisuke Sakamoto; Hironori Haga; Yoji Maetani; Kohei Ogawa; Yasuhiro Ogura; Fumitaka Oike; Hiroto Egawa; Shinji Uemoto
Journal:  Dig Dis       Date:  2007       Impact factor: 2.404

9.  Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database.

Authors:  Christian Toso; Sonal Asthana; David L Bigam; A M James Shapiro; Norman M Kneteman
Journal:  Hepatology       Date:  2009-03       Impact factor: 17.425

10.  Preemptive therapy for hepatitis C virus after living-donor liver transplantation.

Authors:  Yasuhiko Sugawara; Masatoshi Makuuchi; Yuichi Matsui; Yoji Kishi; Nobuhisa Akamatsu; Junichi Kaneko; Norihiro Kokudo
Journal:  Transplantation       Date:  2004-11-15       Impact factor: 4.939
View more
  8 in total

Review 1.  MicroRNAs: Novel players in the diagnosis and treatment of cancer cachexia (Review).

Authors:  Xin Li; Lidong Du; Qiang Liu; Zhong Lu
Journal:  Exp Ther Med       Date:  2022-05-16       Impact factor: 2.751

2.  Preoperative Visceral Adiposity and Muscularity Predict Poor Outcomes after Hepatectomy for Hepatocellular Carcinoma.

Authors:  Yuhei Hamaguchi; Toshimi Kaido; Shinya Okumura; Atsushi Kobayashi; Hisaya Shirai; Siyuan Yao; Shintaro Yagi; Naoko Kamo; Satoru Seo; Kojiro Taura; Hideaki Okajima; Shinji Uemoto
Journal:  Liver Cancer       Date:  2018-06-05       Impact factor: 11.740

3.  Impact of preoperative chronic renal failure on liver transplantation: a population-based cohort study.

Authors:  Peter Chi-Ho Chung; Hsiu-Pin Chen; Jr-Rung Lin; Fu-Chao Liu; Huang-Ping Yu
Journal:  Ther Clin Risk Manag       Date:  2016-12-14       Impact factor: 2.423

Review 4.  18F-FDG-PET for Assessing Biological Viability and Prognosis in Liver Transplant Patients with Hepatocellular Carcinoma.

Authors:  Arno Kornberg; Martina Schernhammer; Helmut Friess
Journal:  J Clin Transl Hepatol       Date:  2017-07-08

5.  Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma.

Authors:  Hitomi Takada; Masayuki Kurosaki; Hiroyuki Nakanishi; Yuka Takahashi; Jun Itakura; Kaoru Tsuchiya; Yutaka Yasui; Nobuharu Tamaki; Kenta Takaura; Yasuyuki Komiyama; Mayu Higuchi; Youhei Kubota; Wann Wang; Mao Okada; Nobuyuki Enomoto; Namiki Izumi
Journal:  PLoS One       Date:  2018-06-18       Impact factor: 3.240

6.  Sarcopenia as a predictor of post-transplant tumor recurrence after living donor liver transplantation for hepatocellular carcinoma beyond the Milan criteria.

Authors:  Young Ri Kim; Sukhee Park; Sangbin Han; Joong Hyun Ahn; Seonwoo Kim; Dong Hyun Sinn; Woo Kyoung Jeong; Justin S Ko; Mi Sook Gwak; Gaab Soo Kim
Journal:  Sci Rep       Date:  2018-05-08       Impact factor: 4.379

Review 7.  Clinical impact of sarcopenia assessment in patients with hepatocellular carcinoma undergoing treatments.

Authors:  Giovanni Marasco; Matteo Serenari; Matteo Renzulli; Luigina Vanessa Alemanni; Benedetta Rossini; Irene Pettinari; Elton Dajti; Federico Ravaioli; Rita Golfieri; Matteo Cescon; Davide Festi; Antonio Colecchia
Journal:  J Gastroenterol       Date:  2020-08-03       Impact factor: 7.527

8.  Are the criteria always right? Assessment of hepatocellular carcinoma cases in living zzm321990donor liver transplantation at a high-volume center

Authors:  Yücel Yankol; Gültekin Hoş; Turan Kanmaz; Nesimi Mecit; Yilmaz Çakaloğlu; Münci Kalayoğlu; Koray S Acarli
Journal:  Turk J Med Sci       Date:  2021-10-21       Impact factor: 0.973
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.